Sleeping sickness : human African trypanosomiasis
World Health Organization. Human African Trypanosomisis Control Programme. 1997. (1997). Sleeping sickness : human African trypanosomiasis. Geneva : World Health Organization. http://www.who.int/iris/handle/10665/63588
DescriptionProduced with the support of Secrétariat d'Etat à la Coopération (France) and with the collaboration of OCEAC and OCCGE/PR
Gov't Doc #WHO/CTD/HATCP/97.5
Other Language Versionsfrançais
MetadataShow full item record
Showing items related by title and MeSH subject.
Report on a meeting of the Product Development Team for African Trypanosomiasis Chemotherapy to review the comparative study of the 14-day versus the 7-day treatment of late stage t.b. gamiense African trypanosomiasis with eflornithine : WHO, Geneva, 14 July 1998 UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Product Development Team for African Trypanosomiasis Chemotherapy (TDR/DDR/98.1, 1998)
Control of human african trypanosomiasis: a strategy for the African Region: report of the Regional Director Regional Committee for Africa, 55 (AFR/RC55/11, 2011-06-23)1. Human African trypanosomiasis (HAT) is caused by trypanosomes that are transmitted by the tsetse fly. HAT is the only vector-borne parasitic disease with a geographical distribution limited to the African continent. Populations in the age group 15-45 years living in remote rural areas are the most affected, leading to economic loss and social misery. 2. In the early 1960s, the prevalence of HAT had been reduced to very low levels (prevalence rate less than one case per 10 000 inhabitants). Unfortunately, due to lack of regular surveillance ...